华蟾素注射液治疗肺癌的系统评价  

Systematic Review of Cinobufacini Injection for Lung Cancer

作　　者：罗川 高波 边宝林[2] 赵海誉[2] 

机构地区：[1]安徽华润金蟾药业股份有限公司,安徽淮北235000 [2]中国中医科学院中药研究所,北京100700

出　　处：《中国实验方剂学杂志》2016年第8期208-214,共7页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：国家"重大新药创制"科技重大专项(2009ZX09103404;2013ZX09102025)

摘　　要：目的:系统评价华蟾素注射液治疗肺癌的疗效和安全性。方法:计算机检索Cochrane图书馆临床对照试验数据库,Pub Med,CNKI,CBM,中文科技期刊数据库VIP等,检索时间从建库截止至2014年12月按纳入排除标准选择文献,评价质量。在按测量指标和干预措施进行亚组分析后,对同质研究进行Meta分析。结果:共纳入17个研究,合计1 279例肺癌患者。所有文献均未描述分配隐藏方法,未实施盲法。结论:华蟾素注射液联用西药(化疗/"化疗"+常规)治疗肺癌在提高远期生存率、生活质量及近期有效率一定程度上优于单纯西药。Objective： To systemically evaluate the effectiveness and safety of Cinobufacini injection for lung cancer. Method： We searched The Cochrane Central Register of Controlled Trials（ CCTR）,Pub Med,CNKI,CBM,VIP databases up to Dce. 2014. The methodological quality assessment and data extraction of the included studies were conducted by two reviewers independently according to the inclusion and exclusion criteria.Meta-analysis was performed for homogeneous studies using Rev Man 4. 2. 10 software after subgroup analysis of the measurement indicators and intervention measures. Result： A total of 17 studies involving 1 279 patients were included. None of the studies mentioned allocation concealment method and no blinding method was performed.Conclusion： In the treatment of lung cancer,the combination of cinobufacini injection and western medicine is superior to western medicine alone for the long-term survival rate,quality of life and short-term efficacy.

关 键 词：华蟾素 肺癌 疗效 安全性 系统评价 

分 类 号：R287[医药卫生—中药学]